

PTO/SB/D8A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/597,545-Conf. #2550
				Filing Date	January 28, 2005
				First Named Inventor	Benny V. Jensen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	HOI-11502/16

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
/J.K./	AA*	US-6,007,798		12-28-1999	Bohn et al.	
/J.K./	AB*	US-20030083322-A1		05-01-2003	KRAEMER et al.	
/J.K./	AC*	US-5,728,373		03-17-1998	Alert et al.	
/J.K./	AD*	US-20010053347-A1		12-20-2001	VARANI et al.	
/J.K./	AE*	US-20050142092-A1		06-30-2005	Lintner	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁴ -Kind Code ⁵ (if known)					
/J.K./	BA	FR-FR2805744		09-07-2001	Sederma Sa		
/J.K./	BB	DE-DE19900749		07-13-2000	Aventis Pharma Gmbh		
/J.K./	BC	JP-JP2002284647		10-03-2002	Cosmo Products Kk		
/J.K./	BD	DE-DE19604190		08-07-1997	Hoechst Ag		
/J.K./	BE	WO-WO 96/26712		09-06-1996	Handelman Joseph H et al.		
/J.K./	BF	WO-WO 02/064088		08-22-2002	Niazi Sarfaraz K		
/J.K./	BG	WO-WO 9404129		03-03-1994	Beiersdorf Ag et al.		
/J.K./	BH	WO-WO 03066141		08-21-2003	Sederma et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.93(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
/J.K./	CA	KLIGMAN et al., Collagen Loss In Photoaged Human Skin Is Overestimated By Histochemistry; Photodermatol Photolmmunol & Photomed; 2000; Pages 224-228		
/J.K./	CB	BERNSTEIN et al., The Biology of Angiotensin II Receptors; American Journal of Kidney Diseases, Vol 22, No. 5; Pages 745-754; November 1993		
/J.K./	CC	PIERRE-LOUIS THARAUX et al., Angiotensin II Activates Collagen I Gene Through A Mechanism Involving The MAP/ER Kinase Pathway; American Heart Association, Inc.; Pages 330-336; February 2000;		
/J.K./	CD	PATTEN et al., Effects of Angiotensin II Receptor Blockade Versus Angiotensin-Converting-Enzyme Inhibition On Ventricular Remodelling Following Myocardial Infarction In The Mouse; The Biochemical Society and the Medical Research Society; Pages 109-118; 2003		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jody Karol/	Date Considered	05/19/2010
-----------------------	--------------	--------------------	------------